Medical Devices

Labcorp and Community Clinical Oncology Research Network Collaborate to Assess Social and Economic Impacts of Disparities in Cancer Care

Retrieved on: 
Thursday, August 19, 2021
Technology, Medical Devices, Clinical Trials, Practice Management, Biotechnology, Health, Pharmaceutical, Data Management, Oncology, Face, Prospective, LLC, LH, American Association for Cancer Research, Drug development, Biobank, Cancer, OF, Community Oncology Alliance, Diagnosis, Biomarker, Research, Registry, Prevalence, Health, American Association, Hospital, NYSE, Precision medicine, Multimedia, Awareness, Clinical trial, MPH, Patient, Journal of the National Comprehensive Cancer Network, LinkedIn, FACP, CEO, Publication, Association, Oncology, National Comprehensive Cancer Network, Pharmaceutical industry, Medical imaging, CCORN (Community Clinical Oncology Research Network), Labcorp, CCORN (COMMUNITY CLINICAL ONCOLOGY RESEARCH NETWORK), LABCORP

Labcorp (NYSE: LH), a leading global life sciences company, and Community Clinical Oncology Research Network, LLC (CCORN), a leading research organization, today announced their collaboration to better understand the impact of disparities in precision medicine for people with cancer.

Key Points: 
  • Labcorp (NYSE: LH), a leading global life sciences company, and Community Clinical Oncology Research Network, LLC (CCORN), a leading research organization, today announced their collaboration to better understand the impact of disparities in precision medicine for people with cancer.
  • Information gathered from a patient registry and biobank will be used to help design future cancer clinical trials in diverse populations.
  • Additionally, a 2020 American Association for Cancer Research report on cancer disparities estimated that 34% of cancer deaths among U.S. adults age 25 to 74 could be prevented if disparities in clinical trial participation were actively addressed.
  • Their mission is to close the widespread disparities in cancer burden, cancer care and precision medicine.

Pulse Biosciences Announces Appointment of Mitchell E. Levinson as Chief Strategy Officer

Retrieved on: 
Thursday, August 19, 2021
Biotechnology, Health, Medical Devices, Microbiology, Company, University, Allergan, Â, Quality of life, Fat removal procedures, Mitchell, U.S. Securities and Exchange Commission, Zeltiq Aesthetics, NPS, Computer, Security (finance), Nasdaq, List of life sciences, Neurology, Health, University of Phoenix, Board, Patient, CEO, University of California, San Diego, Mechanical engineering, Otorhinolaryngology, San Diego, Technology, Dermatology, Management, Medical imaging

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX System powered by Nano-Pulse Stimulation (NPS) technology, today announced the appointment of Mitchell E. Levinson to the newly created role of Chief Strategy Officer, effective immediately, in addition to the continuation of his role as a member of the Pulse Biosciences Board of Directors.

Key Points: 
  • Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX System powered by Nano-Pulse Stimulation (NPS) technology, today announced the appointment of Mitchell E. Levinson to the newly created role of Chief Strategy Officer, effective immediately, in addition to the continuation of his role as a member of the Pulse Biosciences Board of Directors.
  • Mr. Levinson was the first employee and startup CEO for Zeltiq Aesthetics, the CoolSculpting company, acquired by Allergan in 2017.
  • As one of Pulse Biosciences early board members, I have had the privilege of working closely with the board and management team over the years to develop the companys strategy and vision for our highly differentiated and proprietary NPS technology, said Mitchell E. Levinson, Director and Chief Strategy Officer of Pulse Biosciences.
  • Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Fuse Medical, Inc. Announces Initial Launch of Orbitum™ Compression Staple System

Retrieved on: 
Thursday, August 19, 2021
Research, Medical Devices, Surgery, Hospitals, Other Health, Biotechnology, General Health, Health, Science, Other Science, Company, Joint, Hand, Operation Time, RADIUS, VI, U.S. Securities and Exchange Commission, Orientation, Medicine, Trauma, Efficiency, Elasticity, Leg, Compression, Foot, Physics, Fuse, Sports medicine, Solution, DPM, Security (finance), Medical device, Ceramic

Fuse Medical, Inc. (OTCPINK: FZMD) (Fuse or the Company) an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace, announced the initial launch and first implantations of the Fuse Orbitum Compression Staple.

Key Points: 
  • Fuse Medical, Inc. (OTCPINK: FZMD) (Fuse or the Company) an emerging manufacturer and distributor of innovative medical devices for the orthopedic and spine marketplace, announced the initial launch and first implantations of the Fuse Orbitum Compression Staple.
  • The patented Orbitum Staple System, consisting of the Orbitum VI and Orbitum X Staples, indicated for use in the foot or hand, is a significant departure from legacy bone staple fixation.
  • The industrys current designs revolve around staple leg compression, yet the actual need is to achieve full bone compression.
  • The Orbitum X round staple provides circumferential compression and can be utilized for three or four corner fusions with a single implant.

Henry Schein Partners With NGOs to Provide Health Care Products to Aid Haitian Earthquake Victims and Opens Disaster Relief Fund

Retrieved on: 
Thursday, August 19, 2021
Philanthropy, Health, Medical Devices, Other Health, Fund Raising, Dental, Foundation, Company, CMMB, PPE, Personal protective equipment, Non-governmental organization, MAP International, MedShare, Government, Nasdaq, Social responsibility, Success, Supply chain, Fund, World Vision International, S&P, MAP, Philosophy, Foundation, Pan American Health Organization, CMMB (Catholic Medical Mission Board), Board, Water purification, Solution, Education, Schein, Health equity, PAHO, NGO, Pharmaceutical industry, Management, Henry Schein Cares, Henry Schein, Inc., HENRY SCHEIN CARES, HENRY SCHEIN, INC.

In response to the devastating earthquake in Haiti, Henry Schein, Inc. (Nasdaq: HSIC) is aiding relief efforts by partnering with several non-governmental organizations (NGOs) responding to the disaster, as well as by opening its disaster relief fund.

Key Points: 
  • In response to the devastating earthquake in Haiti, Henry Schein, Inc. (Nasdaq: HSIC) is aiding relief efforts by partnering with several non-governmental organizations (NGOs) responding to the disaster, as well as by opening its disaster relief fund.
  • In addition to this vital product support, Henry Schein is opening the 2021 Disaster Relief Fund through the Henry Schein Cares Foundation to support relief efforts in Haiti.
  • Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology.
  • These solutions also support dental and medical laboratories, government and institutional health care clinics , as well as other alternate care sites.

Outlook on the Trauma Fixation Devices Global Market to 2027 - Increase in the Prevalence of Road Accidents is the Main Driving Factor - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 19, 2021
Biotechnology, Health, Surgery, Medical Devices, Industry, Wilford Hall Ambulatory Surgical Center, Growth, Human, World Health Organization, Prevalence, Asia, Hospital, External fixation, WHO, Smith & Nephew, Plate, Internal fixation, Accident

Increase in prevalence of road accidents is the main driving factor which is expected to boost the global trauma fixation devices market growth.

Key Points: 
  • Increase in prevalence of road accidents is the main driving factor which is expected to boost the global trauma fixation devices market growth.
  • Further, increase in incidences of bone degenerative diseases will have the positive impact on global trauma fixation devices market growth.
  • Moreover, Rise in technical advancements and innovations in medical devices industry which are expected to fuel the global trauma fixation devices market growth.
  • However, lack of trained professional is the restraining factor which is expected to hamper the global trauma fixation devices market growth.

Global External Urinary Catheters Market to 2026 - Insights, Competitive Landscape and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 19, 2021
Medical Devices, Health, Cardiac catheterization, Gaps, CAGR, Catheter-associated urinary tract infection, Lists of people executed in the United States, Review, CAUTI, MM, Prevalence, SME, Incidence, Lists of diseases, Multiple sclerosis, Medical imaging, Public relations

This segment illustrates the market of external urinary catheters across the 7MM and how the market is expected to rise in the study period (2018 to 2026), at a significant CAGR.

Key Points: 
  • This segment illustrates the market of external urinary catheters across the 7MM and how the market is expected to rise in the study period (2018 to 2026), at a significant CAGR.
  • Additionally, an all-inclusive account of the currently available external urinary catheters is provided, which will have an impact on the future market of external urinary catheters.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the external urinary catheters market.
  • The report helps in developing business strategies by understanding trends shaping and driving the external urinary catheters market.

Guided Therapeutics Receives Notification of Successful Clinical Trial Regulatory Review and $133,000 Payment from China

Retrieved on: 
Thursday, August 19, 2021
Research, Hardware, Oncology, Medical Devices, Technology, Photography, Clinical Trials, Science, Biotechnology, FDA, Other Science, Health, Cancer, Biophotonics, Obstetrics, OTCQB, Population, Death, SMI, National Medical Products Administration, Department, Trial of the century, SEC, Research, World Health Organization, Disease, Therapy, Fudan University, World, Mortality, Risk, News, CEO, FDA, Woman, Cervical cancer, Annual report, Technology, Pharmaceutical industry, Medical imaging

GTHP also received a payment of $133,000 from its Chinese co-manufacturing partner and distributor for China, Shandong Yaohua Medical Instrument Corporation (SMI).

Key Points: 
  • GTHP also received a payment of $133,000 from its Chinese co-manufacturing partner and distributor for China, Shandong Yaohua Medical Instrument Corporation (SMI).
  • The funds will be used to supply SMI with parts and advice for the Chinese clinical study.
  • Parts are expected to ship this quarter and additional participating clinical sites announced over the next few weeks.
  • We continue to be encouraged by the regulatory approvals from China, said Gene Cartwright, CEO of Guided Therapeutics.

Skyway Capital Markets Adds Leading Healthcare Business Expert to Advisory Board

Retrieved on: 
Thursday, August 19, 2021
Data Management, Practice Management, Other Science, Technology, Research, General Health, Other Health, Pharmaceutical, Oncology, Medical Devices, Insurance, Finance, Banking, Clinical Trials, Professional Services, Biotechnology, Other Technology, Software, Health, Networks, Science, Linda, Dartmouth, Capital market, Health care, Community Oncology Alliance, Tuck School of Business, Thayer School of Engineering, Business, Chief executive officer, Medicare, ISO, SVP, Vanderbilt, Oppenheimer Holdings, Multimedia, Oppenheimer, Community leader, Donaldson, Lufkin & Jenrette, Advisory board, Dartmouth College, CEO, FDA, Management

Skyway Capital Markets is pleased to welcome Wes Chapman to its Advisory Board, a highly regarded group of experts that represent a broad spectrum of industries and who serve as advisors to the Skyway leadership team.

Key Points: 
  • Skyway Capital Markets is pleased to welcome Wes Chapman to its Advisory Board, a highly regarded group of experts that represent a broad spectrum of industries and who serve as advisors to the Skyway leadership team.
  • He is an expert in medical quality and value-based care reimbursement systems, teaching these subjects at Dartmouth and Vanderbilt.
  • We are honored to have Wes serve on our Advisory Board, and we look forward to his valuable strategic advice as we continue to grow our Healthcare practice, remarked Skyway CEO Russ Hunt.
  • Skyway Capital Markets works with middle market companies, public and private, through customized capital services that include corporate finance, mergers & acquisitions and recapitalization.

Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer

Retrieved on: 
Thursday, August 19, 2021
Oncology, Medical Devices, Health, Other Health, General Health, Biotechnology, Terminology, Private Securities Litigation Reform Act, Life expectancy, Society, University, Quality of life, Twitter, Internet, Blood, Cancer, U.S. Securities and Exchange Commission, SNO, Large-cell lung carcinoma, Diagnosis, SEC, Survival, Biomarker, Physician, Lung cancer, Risk, Central nervous system, Pakistan Society of Neuro-Oncology, Forward-looking statement, LMC, Mutation, Review, Public health, Medical director, Membrane, COVID-19 testing, Patient, NSCLC, Spinal cord, LinkedIn, Conference, Brain, Cerebrospinal fluid, COVID-19, Security (finance), Medical imaging

More than 198,000 patients are diagnosed with non-small cell lung cancer (NSCLC) each year.

Key Points: 
  • More than 198,000 patients are diagnosed with non-small cell lung cancer (NSCLC) each year.
  • The retrospective study, conducted at the University of Utah Huntsman Cancer Institute, used Biocepts CNSide assay to detect and analyze tumor cells in the cerebrospinal fluid of 15 unique patients.
  • Of the samples analyzed, CNSide detected tumor cells in 100% of samples with LMC, while cytology detected tumor cells in just 40% of the samples.
  • This study shows that using CNSide to interrogate the cerebrospinal fluid for actionable mutations provides the information needed to determine the appropriate treatment for patients with LMC.

Global Specialty Medical Chairs Market Trajectory & Analytics to 2027: Examination Chairs Forecast for 5.3% CAGR to Reach US$1.9 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 19, 2021
Health, Medical Supplies, Medical Devices, CAGR, Growth, Treatment, COVID-19, Pet

The "Specialty Medical Chairs - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Specialty Medical Chairs - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Specialty Medical Chairs estimated at US$5 Billion in the year 2020, is projected to reach a revised size of US$7.3 Billion by 2027, growing at a CAGR of 5.5% over the analysis period 2020-2027.
  • Examination Chairs, one of the segments analyzed in the report, is projected to record a 5.3% CAGR and reach US$1.9 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 8.4% CAGR
    The Specialty Medical Chairs market in the U.S. is estimated at US$1.4 Billion in the year 2020.